- Home
- MYGN vs DFIN Comparison
MYGN vs DFIN Comparison
Compare MYGN & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- DFIN
- Stock Information
- Founded
- MYGN 1991
- DFIN 1983
- Country
- MYGN United States
- DFIN United States
- Employees
- MYGN N/A
- DFIN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DFIN Other Consumer Services
- Sector
- MYGN Health Care
- DFIN Consumer Discretionary
- Exchange
- MYGN Nasdaq
- DFIN Nasdaq
- Market Cap
- MYGN 2.0B
- DFIN 1.9B
- IPO Year
- MYGN 1995
- DFIN N/A
- Fundamental
- Price
- MYGN $13.50
- DFIN $60.68
- Analyst Decision
- MYGN Hold
- DFIN Strong Buy
- Analyst Count
- MYGN 11
- DFIN 3
- Target Price
- MYGN $24.27
- DFIN $76.33
- AVG Volume (30 Days)
- MYGN 1.1M
- DFIN 220.6K
- Earning Date
- MYGN 02-25-2025
- DFIN 02-18-2025
- Dividend Yield
- MYGN N/A
- DFIN N/A
- EPS Growth
- MYGN N/A
- DFIN 18.18
- EPS
- MYGN N/A
- DFIN 3.18
- Revenue
- MYGN $823,600,000.00
- DFIN $802,100,000.00
- Revenue This Year
- MYGN $13.82
- DFIN $1.75
- Revenue Next Year
- MYGN $4.59
- DFIN $4.27
- P/E Ratio
- MYGN N/A
- DFIN $19.71
- Revenue Growth
- MYGN 12.15
- DFIN 1.74
- 52 Week Low
- MYGN $12.87
- DFIN $56.02
- 52 Week High
- MYGN $29.30
- DFIN $71.01
- Technical
- Relative Strength Index (RSI)
- MYGN 32.61
- DFIN 45.11
- Support Level
- MYGN $13.04
- DFIN $60.24
- Resistance Level
- MYGN $13.77
- DFIN $63.74
- Average True Range (ATR)
- MYGN 0.60
- DFIN 1.61
- MACD
- MYGN 0.14
- DFIN 0.08
- Stochastic Oscillator
- MYGN 24.51
- DFIN 16.28
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.